Department of Bioengineering and Technology, Gauhati University, Guwahati, Assam, India; Multidisciplinary Research Unit, Department of Health Research, ICMR, Fakhruddin Ali Ahmed Medical College, Barpeta, Assam, India.
Department of Gynecologic Oncology, Dr B. Borooah Cancer Institute, Guwahati, Assam, India.
Curr Probl Cancer. 2020 Oct;44(5):100556. doi: 10.1016/j.currproblcancer.2020.100556. Epub 2020 Feb 3.
Molecular pathogenesis of Triple-negative breast cancer (TNBC) is inconclusively documented from resource limited countries and hence there is a lack of available targeted therapy for clinical interventions. Compared to other breast cancer subtypes, TNBC is more aggressive, higher recurrence rate, and higher prevalence in younger premenopausal women. Sporadic literature indicates predominance of TNBC in all reported breast cancer cases from Northeast India.
This study was conducted to evaluate the candidature of panel of key molecular markers involved in the development and progression of TNBC for prognosis and futuristic tailored targeted therapy.
We analyzed the clinicopathological characterized and immunohistochemically screened the differential expression of key molecular markers involved in the development and progression of in TNBC cases vis-a-vis non-TNBC and autopsy-based control samples.
TNBC tends to display at an early reproductive age and is more aggressive in nature. Further, the differential expression of 2 specific markers viz., epidermal growth factor receptor (EGFR) and FolR1 was higher in TNBC cases compared to controls and non-TNBC (both in terms of susceptibility and specificity), clinical staging in TNBC cases (severity) and mortality (outcome). Although Ki67 and vascular endothelial growth factor expression also correlated with severity and outcome of the disease but their differences in non-TNBC cases were not significantly differentiable compared to TNBC.
The study indicates that EGFR and FolR1 could serve as useful biomarkers to determine TNBC prognosis. Further studies will be needed to evaluate EGFR and Folate pathways in order to screen out the molecular targets which may be meaningfully used for clinical stratification, intervention, and treatment.
来自资源有限国家的三阴性乳腺癌（TNBC）的分子发病机制尚未得到明确证实，因此缺乏可用于临床干预的现有靶向治疗方法。与其他乳腺癌亚型相比，TNBC更具侵袭性、复发率更高，且在年轻绝经前女性中更为常见。零星文献表明，在印度东北部所有报告的乳腺癌病例中，TNBC 都更为普遍。
本研究旨在评估参与 TNBC 发生和进展的关键分子标志物在预后和未来个体化靶向治疗中的候选资格。
我们分析了临床病理特征，并对 TNBC 病例中涉及 TNBC 发生和进展的关键分子标志物进行了免疫组织化学筛选，与非 TNBC 和尸检对照样本进行了比较。
TNBC 往往在早期生育年龄发病，且性质更为侵袭性。此外，与对照组和非 TNBC 相比（无论是在易感性还是特异性方面），TNBC 病例中 2 种特定标志物（表皮生长因子受体 [EGFR] 和 FolR1）的差异表达更高，TNBC 病例的临床分期（严重程度）和死亡率（结果）也是如此。尽管 Ki67 和血管内皮生长因子的表达也与疾病的严重程度和结果相关，但与 TNBC 相比，其在非 TNBC 病例中的差异并不具有显著可区分性。
该研究表明，EGFR 和 FolR1 可作为确定 TNBC 预后的有用生物标志物。需要进一步研究 EGFR 和叶酸途径，以筛选可能对临床分层、干预和治疗有意义的分子靶标。
Zotero 插件